Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.33 |
| ▸ | CNR1 | P21554 | 3/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | SLC6A9 | P48067 | 4/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6521493 | 0.97 | F2 (0.37) | F2TP53CACNA1HCYP2D6DDR1 | |
| SCHEMBL3408094 | 0.86 | F2 (0.36) | F2TP53CACNA1HDDR1SLC6A9 | |
| SCHEMBL3407502 | 0.86 | KDM4E (0.37) | F2TP53CACNA1HCYP2D6SLC6A9 | |
| SCHEMBL6525306 | 0.86 | F2 (0.35) | F2TP53CACNA1HDDR1SLC6A9 | |
| SCHEMBL3406126 | 0.84 | F2 (0.38) | F2TP53DDR1HRH3GRIA2 | |
| SCHEMBL3401787 | 0.84 | F2 (0.39) | F2TP53DDR1HRH3GRIA2 | |
| SCHEMBL976717 | 0.84 | F2 (0.39) | F2TP53DDR1CNR1SLC6A9 | |
| SCHEMBL3405699 | 0.83 | BACE1 (0.41) | F2SLC6A9HRH3BACE1 | |
| SCHEMBL3403100 | 0.83 | BACE1 (0.38) | F2TP53CACNA1HDDR1CNR1 | |
| SCHEMBL6523366 | 0.83 | F2 (0.34) | F2DDR1SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053908-A1 | AZETIDINE-DERIVED COMPOUNDS, PREPARATION METHOD THEREFOR AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-03-03 | — | — | US | claimed |
| EP-2254862-A2 | AZETIDINE-DERIVED COMPOUNDS, PREPARATION METHOD THEREFOR AND THERAPEUTIC USE OF SAME | Sanofi-Aventis (FR) | 2010-12-01 | — | — | EP | claimed |
| WO-2009118473-A2 | AZETIDINE-DERIVED COMPOUNDS, PREPARATION METHOD THEREFOR AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2009-10-01 | — | — | WO | claimed |
| US-20110053908-A1 | AZETIDINE-DERIVED COMPOUNDS, PREPARATION METHOD THEREFOR AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-03-03 | — | — | US | disclosed |
| EP-2254862-A2 | AZETIDINE-DERIVED COMPOUNDS, PREPARATION METHOD THEREFOR AND THERAPEUTIC USE OF SAME | Sanofi-Aventis (FR) | 2010-12-01 | — | — | EP | disclosed |
| WO-2009118473-A2 | AZETIDINE-DERIVED COMPOUNDS, PREPARATION METHOD THEREFOR AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053908-A1 | AZETIDINE-DERIVED COMPOUNDS, PREPARATION METHOD THEREFOR AND THERAPEUTIC USE OF SAME | QDPR, NHERF1, GABRR1 | F2 1098/4885TP53 2179/4885CACNA1H 979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.